Hematological evaluation of splenectomized and non-splenectomized transfusion dependent patients with thalassemia
DOI:
https://doi.org/10.18203/2320-6012.ijrms20261320Keywords:
Transfusion dependent thalassemia, Thalassemia, Splenomegaly, Splenectomy, Iron chelation, Serum ferritinAbstract
Background: Thalassemia is a group of blood disorders caused by decreased or absent synthesis of globin chains, with β-thalassemia leading to ineffective erythropoiesis, severe anemia, and the need for lifelong transfusions. Frequent transfusions can cause iron overload, and many transfusion-dependent patients require splenectomy to manage hypersplenism, though the procedure carries potential risks and its benefit on transfusion reduction remains debated. The aim of the study was to compare the hematological profile and iron overload status between splenectomized and non-splenectomized transfusion-dependent patients with thalassemia.
Methods: This cross-sectional comparative study at the department of transfusion medicine, Bangabandhu Sheikh Mujib Medical University (BSMMU), Dhaka, from December 2021 to October 2022, included 60 transfusion-dependent thalassemia patients (30 splenectomized, 30 non-splenectomized). Sociodemographic, nutritional, clinical, transfusion, and laboratory data (CBC, PBF, serum ferritin) were collected and analyzed using SPSS version 24 (p < 0.05).
Results: Among 60 patients, splenectomized individuals were more often underweight (76.7% versus 46.7%), had higher hemoglobin (7.26 versus 6.78 gm/dl), MCV (75.64 versus 69.99 fl), WBC (12.24 versus 9.31 ×103/l), platelets (556 versus 210 ×10³/L), and ferritin (5843.98 versus 3253.32 ng/mL), while non-splenectomized patients required more frequent transfusions ≤4 weeks (83.3% versus 40%) and had more severe anemia (63.3% versus 36.7%).
Conclusions: Splenectomy in transfusion-dependent thalassemia improves hemoglobin and blood counts but does not reduce iron overload, highlighting the need for continued monitoring and management.
References
Weatherall D. Thalassemia: the long road from the bedside through the laboratory to the community. Nat Med. 2010;16(10):1112-5.
Lichtman MA, Thalassemias. In: Kaushansky K, Lichtman MA, Prchal JT, Levi MM, Press OW, eds. Williams Hematology. New York: McGraw-Hill; 2005.
Lukens JN, Lee GR, Foerster J, Lukens JN, Paraskevas F, Greer JP, et al. The thalassemias and related disorders: quantitative disorders of hemoglobin synthesis. In: Wintrobe’s Clinical Hematology. Philadelphia: Lippincott Williams and Wilkins; 1999:1339-1391.
Taher AT, Vichinsky E, Musallam KM, Cappellini MD, Viprakasit V. Guidelines for the management of non-transfusion dependent thalassaemia (NTDT). In: Thalassaemia International Federation. Publication No 19. Nicosia (Cyprus); 2013.
Cappellini M, Cohen A, Eleftheriou A, Piga A, Porter J, Taher A. Guidelines for the clinical management of thalassaemia. In: Guidelines for the Clinical Management of Thalassaemia. 2nd Revised edition 2014. Thalassaemia International Federation TIF; 2008.
Casale M, Cinque P, Ricchi P, Costantini S, Spasiano A, Prossomariti L, et al. Effect of splenectomy on iron balance in patients with β‐thalassemia major: a long‐term follow‐up. Eur J Haematol. 2013;91(1):69-73.
Isa MM, Thayeb A, Yani A, Hutagalung MB. Post total splenectomy outcome in thalassemia patients. Age. 2019;20:6-5.
Khan WA, Banu B, Amin SK, Selimuzzaman M, Rahman M, Hossain B, et al. Prevalence of beta thalassemia trait and Hb E trait in Bangladeshi school children and health burden of thalassemia in our population. DS (Child) HJ. 2005;21(1):1-7.
Tahura S, Selimuzzaman MD, Khan WA. Thalassaemia prevention: Bangladesh perspective-a current update. Bangladesh J Child Health. 2016;40(1):31-8.
Singh MP, Sudhakar G, Rajasubramaniam S. Prevalence of thalassemia mutations in sickle cell disease population of Madhya Pradesh, Central India. Int J Curr Microbiol App Sci. 2016;5:768-7.
Vichinsky EP. Hemoglobin E syndromes. Hematol Am Soc Hematol Educ Program. 2007;2007(1):79-83.
Sahib HS. Study of growth retardation among patients with thalassemia major: correlation to iron overload. Muthanna Med J. 2025;5(2):77-85.
Kurtoğlu AU, Uğur S, Göçer M, Kurtoğlu E. Effects of splenectomy on natural killer cell levels in β‐thalassemia major patients. J Clin Lab Analysis. 2024;38(9):e25046.
Zhou YL, Zhang XH, Liu TN, Wang L, Yin XL. Splenectomy improves anemia but does not reduce iron burden in patients with hemoglobin H Constant Spring disease. Blood Transfus. 2014;12(4):471-8.
Ayyash H, Sirdah M. Hematological and biochemical evaluation of β-thalassemia major (βTM) patients in Gaza Strip: a cross-sectional study. Int J Health Sci. 2018;12(6):18-24.
Khawaji MM, Hazzazi AA, Ageeli MH, Mawkili YH, Darbashi AH, Abo Kathiyah AMA, et al. Clinical and hematological features among β-thalassemia major patients in Jazan region: a hospital-based study. J Fam Med Prim Care. 2020;9(1):412-7.
Memon AS, Memon R, Muhammad AT, Ali SA, Siddiqui AJ. Splenectomy: does it help in patients with thalassemia major. J Liaquat Uni Med Health. 2017;16:1-2.
Alsalman MH, Al Jabr FA, Eraqe ST, Ali SI, Essa A. Splenectomy perspective for non-malignant hematological disorders: a cross-sectional study in the eastern province of KSA. J Taibah Univ Med Sci. 2022;17(5):774-81.
Ammar SA, Elsayh KI, Zahran AM, Embaby M. Splenectomy for patients with β-thalassemia major: long-term outcomes. Egypt J Surg. 2014;33(4).
Uddin MM, Akteruzzaman S, Rahman T, Hasan AM, Shekhar HU. Pattern of β‐thalassemia and other haemoglobinopathies: a cross‐sectional study in Bangladesh. Int Schol Res Notices. 2012;2012(1):659191.
Sari TT, Gatot D, Akib AA, Bardosono S, Hadinegoro SR, Harahap AR, et al. Immune response of thalassemia major patients in Indonesia with and without splenectomy. Acta Med Indones. 2014;46(3).
Easa ZO. Complications of high serum ferritin level after splenectomy in B thalassemic patients. Kufa Med J. 2009;12(1):243-50.
Uygun V, Kurtoglu E. Iron-chelation therapy with oral chelators in patients with thalassemia major. Hematology. 2013;18(1):50-5.
Aziz AN, Sayed SZ, Ismail DE, Mohamed ZH. Hematological parameters in beta thalassemia major children. Minia J Med Res. 2022;33(2):167-70.
Downloads
Published
How to Cite
Issue
Section
